TY - JOUR
T1 - A Primer on Interstitial Lung Disease and Thoracic Radiation
AU - International Association for the Study of Lung Cancer Advanced Radiation Technology Committee
AU - Goodman, Christopher D
AU - Nijman, Suzan F M
AU - Senan, Suresh
AU - Nossent, Esther J
AU - Ryerson, Christopher J
AU - Dhaliwal, Inderdeep
AU - Qu, Melody
AU - Laba, Joanna
AU - Rodrigues, George
AU - Palma, David A
N1 - Funding Information: Disclosure: Dr. Senan has received departmental research grants from Varian Medical Systems, ViewRay Inc., and AstraZeneca and is a member of the advisory boards for Varian Medical Systems, AstraZeneca, Celgene, and Merck. The remaining authors declare no conflict of interest. Publisher Copyright: © 2020 International Association for the Study of Lung Cancer Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Interstitial lung disease (ILD) is a term used to describe a heterogeneous group of lung disorders with characteristic clinical and imaging features. Patients with ILD are at an increased risk of developing NSCLC, which is frequently medically comorbid, often precluding operative management. In this scenario, radiotherapy (RT) is generally recommended; however, ILD is known to increase the risk of RT-related toxicity. Recommendations for treatment with appropriately individualized risks and benefits are thus dependent on integration of patient-, ILD-, and cancer-specific factors. We aim to provide an overview of ILD for the thoracic oncologist, an assessment of risk of thoracic RT in patients with ILD, and evidence-based recommendations for treatment in a variety of clinical scenarios.
AB - Interstitial lung disease (ILD) is a term used to describe a heterogeneous group of lung disorders with characteristic clinical and imaging features. Patients with ILD are at an increased risk of developing NSCLC, which is frequently medically comorbid, often precluding operative management. In this scenario, radiotherapy (RT) is generally recommended; however, ILD is known to increase the risk of RT-related toxicity. Recommendations for treatment with appropriately individualized risks and benefits are thus dependent on integration of patient-, ILD-, and cancer-specific factors. We aim to provide an overview of ILD for the thoracic oncologist, an assessment of risk of thoracic RT in patients with ILD, and evidence-based recommendations for treatment in a variety of clinical scenarios.
KW - Clinical decision making
KW - Interstitial lung disease
KW - Thoracic radiation
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85082197571&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jtho.2020.02.005
DO - https://doi.org/10.1016/j.jtho.2020.02.005
M3 - Review article
C2 - 32105810
SN - 1556-0864
VL - 15
SP - 902
EP - 913
JO - Journal of thoracic oncology
JF - Journal of thoracic oncology
IS - 6
ER -